Brief: Janux Therapeutics Q3 Basic EPS USD -0.51

Janux Therapeutics

06/11/2024 21:01

Nov 06 (Reuters) - Janux Therapeutics Q3 operating income USD -35.842 million.
* Q3 net income USD -28.059 million
* Q3 collaboration revenue USD 439 thousand
* Q3 operating expenses USD 36.281 million